Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

In the BOLERO-2 trial, everolimus (EVE), an inhibitor of mammalian target of rapamycin, demonstrated significant clinical benefit with an acceptable safety profile when administered with exemestane (EXE) in postmenopausal women with hormone receptor-positive (HR(+)) advanced breast cancer. We report...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Hope S. Rugo, Kathleen I. Pritchard, Michael Gnant, Shinzaburo Noguchi, Martine Piccart, G. N. Hortobagyi, José Baselga, Alejandra Perez, Matthias Geberth, Tibor Csőszi, E. Chouinard, Vichien Srimuninnimit, Puttisak Puttawibul, Janice F. Eakle, Wentao Feng, H. Bauly, Mona El-Hashimy, T Taran, Howard A. Burris
פורמט: Artigo
שפה:אנגלית
יצא לאור: 2014
גישה מקוונת:https://doi.org/10.1093/annonc/mdu009
http://www.annalsofoncology.org/article/S0923753419364981/pdf
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

אינטרנט

https://doi.org/10.1093/annonc/mdu009
http://www.annalsofoncology.org/article/S0923753419364981/pdf

פריטים דומים